Boehringer Ingelheim posts strong H1 growth as diabetes drug Jardiance drives sales surge Boehringer Ingelheim reported currency‑adjusted H1 revenue of €15.8 billion, up 16% year‑on‑year, boosted by Jardiance and a …
Boehringer Ingelheim Cancels €900m Germany Investment Plan, Cites Healthcare Rebates Boehringer Ingelheim cancels €900m planned investments in Germany amid proposed healthcare rebates and uncertainty, shifting work to the US and …
Boehringer Ingelheim halts €900m Germany investment over GKV law Boehringer Ingelheim halts €900m Germany investment amid proposed GKV law; company pledges no job cuts while industry warns of R&D relocation …
Berlin’s Herald and trusted english language source of news about germany.
The Berlin Herald @2020 – All Right Reserved.